AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01690039 — intervention group
Intervention type: DRUG
Intervention: Furosemide-Fludrocortisone-Test (test for urinary acidification)
Description: The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
Study NCT02310191 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid stenting
Description: Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
Study NCT02720926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda,
Description: Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
Study NCT02720926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 day 1 every 21days
Study NCT02720926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: 4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
Study NCT01298024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Neuromuscular Exercise
Description: 30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
Study NCT01298024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Neuromuscular Exercise
Description: 30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
Study NCT00481728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Description: Single dose per patient as determined by protocol.
Study NCT00481728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Filling cystometry
Description: This is a procedure.
Study NCT00481728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravesical neurostimulation
Description: This is a procedure.
Study NCT02821884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of tDCS and NMES
Description: Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
Study NCT02821884 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of tDCS and sham NMES
Description: Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
Study NCT02821884 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combination of sham tDCS and sham NMES
Description: Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
Study NCT02919670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade
Study NCT02919670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02919670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Supportive Care
Study NCT02919670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Supportive Care
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
Study NCT00993096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
Study NCT01332734 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: 2 gram in 1 hour
Study NCT03949075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
Study NCT03949075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
Study NCT01332617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Description: 1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
Study NCT04569045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA+Lidocaine
Description: 20 mg
Study NCT04569045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA
Description: 20 mg
Study NCT01829932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Factor Altered Diet
Study NCT01506531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silo for gastroschisis
Description: silo placed around abdominal contents in gastroschisis patients
Study NCT03840278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bihormonal iLet Bionic Pancreas
Description: Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
Study NCT03840278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin-only Bionic Pancreas
Description: Insulin-only iLet Bionic Pancreas using just insulin
Study NCT01506531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure of gastroschisis
Description: Primary closure of gastroschisis, if possible
Study NCT04024475 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT04301167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: befriending
Description: Participants are new users of the ALONE befriending intervention, which matches participants to volunteer befrienders who visit once weekly for a minimum of 12 months. It is a criterion of study involvement that participants commit to completing at least two data collection timepoints before being matched to a befriender.
Study NCT04127760 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
Study NCT00996762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1250 mg or 1500 mg lapatinib commercial tablet
Study NCT02281721 — intervention group
Intervention type: DEVICE
Intervention: Surpass Flow Diverter(s)
Description: Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
Study NCT02821585 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Counseling
Description: Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
Study NCT02821585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
Study NCT01107470 — intervention group
Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
Study NCT01107470 — intervention group
Intervention type: DRUG
Intervention: hFSH（Fostimon）
Description: After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
Study NCT02021591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Diabetes Detective (MoDD)
Description: MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
Study NCT03218722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-Thrombin Concentrate Complex
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
Study NCT03218722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
Study NCT01163604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
Study NCT01163604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-argatroban treated group
Description: Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
Study NCT02573610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-108
Description: Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
Study NCT02573610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5%
Description: Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
Study NCT03169491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
Study NCT03169491 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
Study NCT03169491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
Study NCT02636972 — intervention group
Intervention type: DRUG
Intervention: OCPs
Description: Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra
Study NCT01280773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
Study NCT02037711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.5%
Description: Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
Study NCT02037711 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
Study NCT02191189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine suspension, into Enterion™ capsule
Study NCT02191189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine suspension
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - single dose
Description: Single ascending doses of ETD002
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - single dose
Description: Single doses of placebo
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - 7 day repeat dose
Description: Twice daily doses of ETD002 for 7 days
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - 7 day repeat dose
Description: Twice daily doses of Placebo for 7 days
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD002 - 14 day repeat dose
Description: Twice daily doses of ETD002 for 14 days
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - 14 day repeat dose
Description: Twice daily doses of Placebo for 14 days
Study NCT04488705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Twice daily doses of salbutamol for 3 days (Days 5, 6 \& 7)
Study NCT03191539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
Study NCT00424372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Smo inhibitor
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study NCT02694224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
Study NCT05121584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of an anterior crown restoration as a final restoration
Description: Placement of an anterior crown restoration as a final restoration
Study NCT05121584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an anterior crown restoration as a final restoration
Description: Placement of an anterior crown restoration as a final restoration
Study NCT03587610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remedial vaccination
Description: * if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~* if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination.
Study NCT02836171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: apatinib was administered in the morning after an overnight fast of at least 10 h
Study NCT02836171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Capsules
Description: rifampicin was administered in the morning 0.5 hours after breakfast
Study NCT01280188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Oral Melt
Description: Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
Study NCT01280188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin intranasal
Description: Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
Study NCT00770120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT01595360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is applied directly to the bleeding site after tooth extraction
Study NCT01595360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-173
Description: It is applied directly to the bleeding site after tooth extraction